Q2 2025 Management View Eric M. Dube, President and CEO, described Q2 2025 as "a standout for Travere, a reflection of strong ...

Travere Therapeutics, Inc. ( ($TVTX) ) has released its Q2 earnings. Here is a breakdown of the information Travere Therapeutics, Inc. presented ...

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to FILSPARI ...

In clinical studies, elevations in aminotransferases (ALT or AST) of at least 3-times the Upper Limit of Normal (ULN) have been observed in up to 3.5% of FILSPARI-treated patients, including cases ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine ...

After meeting with the FDA, Company to submit a supplemental New Drug Application (sNDA) to FDA in Q1 2024 for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in ...

The Food and Drug Administration (FDA) has granted full approval to Filspari ® (sparsentan) to slow kidney function decline in adults with primary immunoglobulin A (IgA) nephropathy who are at ...

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference New data from Phase 2 SPARTAN Study show antifibrotic and anti-inflammatory action of ...

Patients on Filspari achieved mean proteinuria reductions of 49.8% from baseline versus a 15.1% reduction for the control group. Analysts were disappointed by the med’s eGFR miss.

--Travere Therapeutics, Inc., today announced that the U.S. Food and Drug Administration has granted full approval to FILSPARI ® to slow kidney function decline in adults with primary IgAN who ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation ...

Concomitant use of FILSPARI with potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes, or other drugs that raise serum potassium levels may result in hyperkalemia.